<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000641163">
  <TermName>Apo-2L</TermName>
  <TermPronunciation>(AY-poh …)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A cell protein that can attach to certain molecules in some cancer cells and may kill the cells. Apo-2L is being studied in the treatment of cancer. Also called TNF-related apoptosis-inducing ligand, TRAIL, and tumor necrosis factor-related apoptosis-inducing ligand.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000722562" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Apo-2L&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000722561" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Apo-2L&quot;" language="es" id="_4"/>
  <SpanishTermName>Apo-2L</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Proteína celular que se puede unir a ciertas moléculas de algunas células cancerosas y puede destruir las células. Apo-2L está en estudio para el tratamiento de cáncer. También se llama ligando inductor de apoptosis relacionada con el factor de necrosis tumoral, ligando inductor de apoptosis relacionada con el FNT y TRAIL.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-05-08</DateFirstPublished>
</GlossaryTerm>
